山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (6): 33-37.doi: 10.6040/j.issn.1671-7554.0.2021.0481
陈诗鸿
CHEN Shihong
摘要: 糖皮质激素广泛用于治疗各种过敏性和自身免疫性疾病。糖皮质激素性骨质疏松症(GIOP)是长期应用糖皮质激素的不良反应之一,其特征是持续性骨形成下降,伴骨吸收增加,导致骨折发生率增加,给患者带来严重危害。本文对GIOP的发病机制和防治药物进行综述,旨在提高临床医生对GIOP的重视。
中图分类号:
[1] 张学武, 姚海红, 梅轶芳, 等. 全国多中心使用糖皮质激素风湿病患者骨质疏松调查[J]. 中华临床免疫和变态反应杂志, 2017, 11(3): 277-284. ZHANG Xuewu, YAO Haihong, MEI Yifang, et al. Survey on glucocorticosteriod associated osteoporosis in patients with rheumatic diseases in China 2013[J]. Chinese Journal of Allergy and Clinical Immunology, 2017, 11(3): 277-284. [2] Buckley L, Guyatt G, Fink HA, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [J]. Arthrit Rheumatol, 2017, 69(8): 1521-1537. [3] 中国医师协会风湿免疫科医师分会,中华医学会风湿病学分会,中华医学会骨质疏松和骨矿盐疾病分会,等. 2020版中国糖皮质激素性骨质疏松症防治专家共识[J]. 中华内科杂志, 2021, 60(1): 13-21. [4] Lane NE. Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments [J]. Curr Osteoporos Rep, 2019, 17(1): 1-7. [5] Hartmann K, Koenen M, Schauer S, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy [J]. Physiol Rev, 2016, 96(2): 409-447. [6] Hachemi Y, Rapp AE, Picke AK, et al. Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture [J]. J Mol Endocrinol, 2018, 61(1): R75-R90. [7] Yang YJ, Zhu Z, Wang DT, et al. Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPARgamma2 signaling in GIO rats [J]. Acta Pharmacol Sin, 2018, 39(4): 633-641. [8] Han L, Wang B, Wang R, et al. The shift in the balance between osteoblastogenesis and adipogenesis of mesenchymal stem cells mediated by glucocorticoid receptor [J]. Stem Cell Res Ther, 2019, 10(1): 377. [9] Zanotti S, Yu J, Adhikari S, et al. Glucocorticoids inhibit notch target gene expression in osteoblasts [J]. J Cell Biochem, 2018, 119(7): 6016-6023. [10] Deng S, Dai G, Chen S, et al. Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway [J]. Biomed Pharmacother, 2019, 110: 602-608. doi: 10.1016/j.biopha.2018.11.103. [11] Lian W, Ko J, Chen Y, et al. Chaperonin 60 sustains osteoblast autophagy and counteracts glucocorticoid aggravation of osteoporosis by chaperoning RPTOR [J]. Cell Death Dis, 2018, 9(10): 938. [12] Wang T, Liu X, He C. Glucocorticoid-induced autophagy and apoptosis in bone [J]. Apoptosis, 2020, 25(3-4): 157-168. [13] Fu L, Wu W, Sun X, et al. Glucocorticoids enhanced osteoclast autophagy through the PI3K/Akt/mTOR signaling pathway [J]. Calcif Tissue Int, 2020, 107(1): 60-71. [14] Conaway HH, Henning P, Lie A, et al. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity [J]. Bone, 2016, 93: 43-54. doi: 10.1016/j.bone.2016.08.024. [15] Li HX, Li DH, Ma ZM, et al. Defective autophagy in osteoblasts induces endoplasmic reticulum stress and causes remarkable bone loss [J]. Autophagy, 2018, 14(10): 1726-1741. [16] Gan ZY, Fitter S, Vandyke K, et al. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma [J]. Eur J Haematol, 2015, 94(4): 343-354. [17] Florez H, Hernández-Rodríguez J, Muxi A, et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis [J]. Rheumatology, 2020, 59(7): 1574-1580. [18] Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment [J]. Nat Rev Endocrinol, 2020, 16(8): 437-447. [19] Ding L, Hu J, Wang D, et al. Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures [J]. J Clin Endocrinol Metab, 2020, 105(1): dgz023. doi: 10.1210/clinem/dgz023. [20] Matsumoto T, Yamamoto K, Takeuchi T, et al. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients(e-GLORIA)[J]. J Bone Miner Metab, 2020, 38(4): 522-532. [21] Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review[J]. Osteoporos Int, 2019, 30(6): 1145-1156. [22] Bergman J, Nordström A, Nordström P. Alendronate use and the risk of nonvertebral fracture during glucocorticoid therapy: a retrospective cohort study [J]. J Clin Endocrinol Metab, 2018, 103(1): 306-313. [23] Kan S, Yuan Z, Li Y, et al. Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases [J]. Medicine(Baltimore), 2016, 95(25): e3990. doi: 10.1097/MD.0000000000003990. [24] Lv F, Guan Y, Ma D, et al. Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment [J]. Clin Endocrinol(Oxf), 2018, 88(3): 380-387. [25] Saag KG, Pannacciulli N, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial [J]. Arthritis Rheumatol, 2019, 71(7): 1174-1184. [26] Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis [J]. Drug Des Devel Ther, 2019, 13: 2843-2852. doi:10.2147/DDDT.S148654. [27] Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy [J]. Core Evid, 2019, 14: 41-50. doi: 10.2147/CE.S172820. [28] Tanaka I, Tanaka Y, Soen S, et al. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study [J]. J Bone Miner Metab, 2021, 39(3): 446-455. [29] Chandler H, Brooks DJ, Hattersley G, et al. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia [J]. Osteoporos Int, 2019, 30(8): 1607-1616. [30] Yoon SH, Grynpas MD, Mitchell J. Growth hormone increases bone toughness and decreases muscle inflammation in glucocorticoid-treated Mdx mice, model of duchenne muscular dystrophy [J]. J Bone Miner Res, 2019, 34(8): 1473-1486. [31] Sato AY, Cregor M, McAndrews K, et al. Glucocorticoid-induced bone fragility is prevented in female mice by blocking Pyk2/Anoikis signaling [J]. Endocrinology, 2019, 160(7): 1659-1673. [32] Ren H, Yu X, Shen G, et al. miRNA-seq analysis of human vertebrae provides insight into the mechanism underlying GIOP [J]. Bone, 2019, 120: 371-386.doi: 10.1016/j.bone.2018.11.013. [33] Shen G, Ren H, Shang Q, et al. Let-7f-5p regulates TGFBR1 in glucocorticoid-inhibited osteoblast differentiation and ameliorates glucocorticoid-induced bone loss [J]. Int J Biol Sci, 2019, 15(10): 2182-2197. [34] Colditz J, Thiele S, Baschant U, et al. Osteogenic Dkk1 mediates glucocorticoid-Induced but not arthritis-induced bone loss [J]. J Bone Miner Res, 2019, 34(7): 1314-1323. [35] Farasat Zaman YZBC. Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid-induced bone growth impairment [J]. FASEB J, 2019, 33(4): 4962-4974. |
[1] | 陈诗鸿,姜冬青,庄向华,李晓博,潘喆,孙爱丽,娄能俊,王殿辉,杜娇娇,宋玉文. 以骨痛为首发表现的原发性胆汁性胆管炎1例[J]. 山东大学学报 (医学版), 2022, 60(8): 98-102. |
[2] | 王洲洋,江蓓,李宪花,甄军晖,杨向东,胡昭,刘广义,裴斐. 感染性心内膜炎、急性肾损伤伴PR3-ANCA阳性患者1例报道[J]. 山东大学学报 (医学版), 2022, 60(2): 60-64. |
[3] | 邢小平. 原发性骨质疏松症诊治思考[J]. 山东大学学报 (医学版), 2021, 59(6): 1-4. |
[4] | 刘萍,宋玉文,王萍,田光伟,郑凤杰,吕丽,杜娇娇,张静,庄向华,陈诗鸿. 维生素D缺乏与2型糖尿病合并抑郁状态的相关性[J]. 山东大学学报 (医学版), 2021, 59(6): 51-56,102. |
[5] | 康成为,刘雷,蒲小兵,谭钢,董长超,晏兆魁. 合并亚临床型甲状腺功能减退的骨质疏松症62例患者骨代谢及骨转换标志物水平分析[J]. 山东大学学报 (医学版), 2020, 58(5): 82-86. |
[6] | 姬原原,包景泊,赵旭,曹鲁宁,崔敏,张娜,于灵芝. 白介素17F促进大鼠成骨细胞增殖、矿化和Runx2、Osterix的表达[J]. 山东大学学报(医学版), 2017, 55(8): 24-29. |
[7] | 徐大霞,侯楠,李晓峰,王闯,孔猛,焦广俊,陈允震. 糖皮质激素性骨质疏松症骨代谢与糖皮质激素用药时间的相关性[J]. 山东大学学报(医学版), 2017, 55(5): 103-107. |
[8] | 彭斐,宋玲,戚向敏,李亚芹,刁艳菲,钊守凤,王莉莉,杨芳,卢恕来,吕文芳,郭大伟. 间歇性张应力对小鼠破骨细胞TRPV5基因表达的影响[J]. 山东大学学报(医学版), 2017, 55(11): 22-26. |
[9] | 吴倩,倪阳,杨清锐,孙红胜. 双眼睑肿胀及双侧颌下包块1例——IgG4相关性疾病的诊断与思考[J]. 山东大学学报(医学版), 2017, 55(11): 93-96. |
[10] | 冯潇雨, 张洪美, 车选强, 康东红. 成骨细胞刺激因子对去卵巢骨质疏松大鼠的治疗效果[J]. 山东大学学报(医学版), 2015, 53(7): 8-12. |
[11] | 张岩. 某医院2014年上半年住院科室 糖皮质激素使用情况调查分析[J]. 山东大学学报(医学版), 2014, 52(S2): 108-111. |
[12] | 张丽, 严红. 2型糖尿病患者骨质疏松情况调查[J]. 山东大学学报(医学版), 2014, 52(S2): 107-107. |
[13] | 刘海俊, 谢敏妍, 陈锦华, 冯洁萍, 邓振波. 替普瑞酮对大剂量激素 治疗患者上消化道的保护作用[J]. 山东大学学报(医学版), 2014, 52(S2): 57-58. |
[14] | 胡苏1,2,逄曙光2,崔莹2,于春晓1,赵家军1,管庆波1. 链脲佐菌素诱导糖尿病大鼠骨髓间充质干细胞成骨分化[J]. 山东大学学报(医学版), 2013, 51(8): 7-12. |
[15] | 张雯雯1,张艳玲1,王杰1,高聆2,于春晓1,阎慧丽1,徐进1. 促甲状腺激素对破骨细胞分化的影响[J]. 山东大学学报(医学版), 2013, 51(4): 6-10. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 684
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 1986
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Cited |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Shared | ||||||||||||||||||||||||||||||||||||||||||||||||||
Discussed |
|